Last reviewed · How we verify
Anakinra injection
At a glance
| Generic name | Anakinra injection |
|---|---|
| Also known as | Kineret |
| Sponsor | University of California, Los Angeles |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Infection requiring antibiotic
- Constipation
- Lung infection
- Injection Site Reaction
- Hypertension
- Hypotension
- Nausea
- Urinary tract infection
- Alanine aminotransferase increased
- Aspartate aminotransferase increased
- Atrial fibrillation
- Anaemia
Key clinical trials
- IL-1 Inhibition in Early TNBC (PHASE2)
- Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes (PHASE2)
- BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction (EARLY_PHASE1)
- Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation (PHASE2)
- ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS (PHASE3)
- Biologic Therapy to Prevent Osteoarthritis After ACL Injury (EARLY_PHASE1)
- Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure (PHASE2)
- Dupilumab_Metastatic NSCLC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anakinra injection CI brief — competitive landscape report
- Anakinra injection updates RSS · CI watch RSS
- University of California, Los Angeles portfolio CI